TGF-β induces the EMT in prostate cancer in vitro via the suppression of E-cadherin levels, and elevates the expression of fibronectin, vimentin [70], and EMT-TFs such as ZEB1 and SNAI1/2 [71]. Here, SNAI1 is linked to prostate cancer.